Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia | Zendy

Frederick J. Raal | Zendy; Robert C. Scott | Zendy; Ransi Somaratne | Zendy; Ian Bridges | Zendy; Gang Li | Zendy; Scott M. Wasserman | Zendy; Evan A. Stein | Zendy

Open Access

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Author(s) -

Frederick J. Raal,

Robert C. Scott,

Ransi Somaratne,

Ian Bridges,

Gang Li,

Scott M. Wasserman,

Evan A. Stein

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.144055

Subject(s) - medicine , familial hypercholesterolemia , pcsk9 , ezetimibe , endocrinology , statin , evolocumab , kexin , placebo , alirocumab , gastroenterology , compound heterozygosity , lipoprotein , cholesterol , ldl receptor , biochemistry , chemistry , mutation , pathology , alternative medicine , apolipoprotein a1 , gene

Despite statin treatment, many patients with heterozygous familial hypercholesterolemia do not reach desired low-density lipoprotein cholesterol (LDL-C) targets. AMG 145, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease, demonstrated significant reductions in LDL-C in phase 1 studies. This phase 2, multicenter, double-blind, randomized, placebo-controlled, dose-ranging study evaluated the efficacy and safety of AMG 145 in heterozygous familial hypercholesterolemia patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research